1.
Full Text
Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone
Cell, ISSN 0092-8674, 06/2015, Volume 161, Issue 7, pp. 1516 - 1526
The 2013–2015 Ebola virus disease (EVD) epidemic is caused by the Makona variant of Ebola virus (EBOV). Early in the epidemic, genome sequencing provided...
DATABASE | RNA VIRUSES | SELECTION | OUTBREAK | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL BIOLOGY | Genome, Viral | Ebolavirus - classification | Sierra Leone - epidemiology | Humans | Hemorrhagic Fever, Ebola - transmission | Ebolavirus - genetics | Hemorrhagic Fever, Ebola - epidemiology | Ebolavirus - isolation & purification | Biological Evolution | Specimen Handling | Disease Outbreaks | Hemorrhagic Fever, Ebola - virology | Mutation | Ebola virus | Virus diseases | Epidemics | Evolutionary biology | Analysis | Genomics | Ebola virus infections | Epidemiology
DATABASE | RNA VIRUSES | SELECTION | OUTBREAK | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL BIOLOGY | Genome, Viral | Ebolavirus - classification | Sierra Leone - epidemiology | Humans | Hemorrhagic Fever, Ebola - transmission | Ebolavirus - genetics | Hemorrhagic Fever, Ebola - epidemiology | Ebolavirus - isolation & purification | Biological Evolution | Specimen Handling | Disease Outbreaks | Hemorrhagic Fever, Ebola - virology | Mutation | Ebola virus | Virus diseases | Epidemics | Evolutionary biology | Analysis | Genomics | Ebola virus infections | Epidemiology
Journal Article
Cell, ISSN 0092-8674, 08/2015, Volume 162, Issue 4, pp. 738 - 750
The 2013–2015 West African epidemic of Ebola virus disease (EVD) reminds us of how little is known about biosafety level 4 viruses. Like Ebola virus, Lassa...
L-RNA | TRANSMISSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADAPTATION | DISEASE | ANCIENT | PATTERNS | CODON USAGE | PURIFYING SELECTION | EBOLA | FEVER | CELL BIOLOGY | Ebola virus | Proteins | Epidemics | Evolutionary biology | Genomics | Reservoirs | Ebola virus infections | Health aspects | Biosafety | Antigenic determinants
L-RNA | TRANSMISSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADAPTATION | DISEASE | ANCIENT | PATTERNS | CODON USAGE | PURIFYING SELECTION | EBOLA | FEVER | CELL BIOLOGY | Ebola virus | Proteins | Epidemics | Evolutionary biology | Genomics | Reservoirs | Ebola virus infections | Health aspects | Biosafety | Antigenic determinants
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2012, Volume 109, Issue 8, pp. 3065 - 3070
The degree to which molecular epidemiology reveals information about the sources and transmission patterns of an outbreak depends on the resolution of the...
Infectious diseases | Sprouts | Hemolytic uremic syndrome | Surveillance | Escherichia coli | Genomes | Crop diversity | Sequencing | Epidemiology | Shipments | Enteroaggregative E. Coli | Enterohemorrhagic E. Coli | Shiga toxin | Food-borne outbreak | enteroaggregative E. coli | HEMOLYTIC-UREMIC SYNDROME | GERMANY | MULTIDISCIPLINARY SCIENCES | FRAMEWORK | food-borne outbreak | enterohemorrhagic E. coli | DNA-SEQUENCING DATA | FRANCE | Escherichia coli Infections - epidemiology | Escherichia coli Infections - genetics | Escherichia coli - genetics | Escherichia coli - isolation & purification | Humans | Escherichia coli Infections - microbiology | Europe - epidemiology | Polymorphism, Single Nucleotide - genetics | Disease Outbreaks - statistics & numerical data | Models, Genetic | Phylogeny | Epidemics | United States | Genomics | Physiological aspects | Genetic aspects | Research | Bacterial genetics | Life Sciences | Escherichia coli Infections | Disease Outbreaks | Europe | Santé publique et épidémiologie | Polymorphism, Single Nucleotide | Biological Sciences
Infectious diseases | Sprouts | Hemolytic uremic syndrome | Surveillance | Escherichia coli | Genomes | Crop diversity | Sequencing | Epidemiology | Shipments | Enteroaggregative E. Coli | Enterohemorrhagic E. Coli | Shiga toxin | Food-borne outbreak | enteroaggregative E. coli | HEMOLYTIC-UREMIC SYNDROME | GERMANY | MULTIDISCIPLINARY SCIENCES | FRAMEWORK | food-borne outbreak | enterohemorrhagic E. coli | DNA-SEQUENCING DATA | FRANCE | Escherichia coli Infections - epidemiology | Escherichia coli Infections - genetics | Escherichia coli - genetics | Escherichia coli - isolation & purification | Humans | Escherichia coli Infections - microbiology | Europe - epidemiology | Polymorphism, Single Nucleotide - genetics | Disease Outbreaks - statistics & numerical data | Models, Genetic | Phylogeny | Epidemics | United States | Genomics | Physiological aspects | Genetic aspects | Research | Bacterial genetics | Life Sciences | Escherichia coli Infections | Disease Outbreaks | Europe | Santé publique et épidémiologie | Polymorphism, Single Nucleotide | Biological Sciences
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 20, pp. 2773 - 2780
Purpose To investigate oxaliplatin combined with fluorouracil-based chemoradiotherapy as preoperative treatment for locally advanced rectal cancer. Patients...
CAPECITABINE | LEUCOVORIN | RADIOCHEMOTHERAPY | ONCOLOGY | I TRIAL | CHEMORADIOTHERAPY | RADIOTHERAPY | HELICAL TOMOTHERAPY | FLUOROURACIL | MEGAVOLTAGE COMPUTED-TOMOGRAPHY | RADIATION-THERAPY | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions | Adult | Dose Fractionation | Female | Neoadjuvant Therapy | Rectal Neoplasms - pathology | Rectal Neoplasms - drug therapy | Adenocarcinoma - radiotherapy | Rectal Neoplasms - surgery | Adenocarcinoma - drug therapy | Rectal Neoplasms - radiotherapy | Medication Adherence | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Italy | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Index Medicus
CAPECITABINE | LEUCOVORIN | RADIOCHEMOTHERAPY | ONCOLOGY | I TRIAL | CHEMORADIOTHERAPY | RADIOTHERAPY | HELICAL TOMOTHERAPY | FLUOROURACIL | MEGAVOLTAGE COMPUTED-TOMOGRAPHY | RADIATION-THERAPY | Adenocarcinoma - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions | Adult | Dose Fractionation | Female | Neoadjuvant Therapy | Rectal Neoplasms - pathology | Rectal Neoplasms - drug therapy | Adenocarcinoma - radiotherapy | Rectal Neoplasms - surgery | Adenocarcinoma - drug therapy | Rectal Neoplasms - radiotherapy | Medication Adherence | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Italy | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 7, pp. 1373 - 1378
Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed...
Adjuvant chemotherapy | Randomized clinical trial | Gastric cancer | Adjuvant treatment | PHASE-III TRIAL | SURGERY | adjuvant chemotherapy | LEUCOVORIN | gastric cancer | ONCOLOGY | S-1 | ADENOCARCINOMA | GASTRECTOMY | randomized clinical trial | adjuvant treatment | CHEMOTHERAPY | Leucovorin - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Fluorouracil - administration & dosage | Humans | Camptothecin - administration & dosage | Combined Modality Therapy | Chemotherapy, Adjuvant | Stomach Neoplasms - drug therapy | Stomach Neoplasms - surgery | Camptothecin - analogs & derivatives | Cisplatin - administration & dosage
Adjuvant chemotherapy | Randomized clinical trial | Gastric cancer | Adjuvant treatment | PHASE-III TRIAL | SURGERY | adjuvant chemotherapy | LEUCOVORIN | gastric cancer | ONCOLOGY | S-1 | ADENOCARCINOMA | GASTRECTOMY | randomized clinical trial | adjuvant treatment | CHEMOTHERAPY | Leucovorin - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Fluorouracil - administration & dosage | Humans | Camptothecin - administration & dosage | Combined Modality Therapy | Chemotherapy, Adjuvant | Stomach Neoplasms - drug therapy | Stomach Neoplasms - surgery | Camptothecin - analogs & derivatives | Cisplatin - administration & dosage
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 05/2019, Volume 321, Issue 20, pp. 1993 - 2002
IMPORTANCE Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy....
COAGULATION | PROTEIN | MEDICINE, GENERAL & INTERNAL | Recombinant Proteins - therapeutic use | Injections, Intravenous | Blood Coagulation Disorders - etiology | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Sepsis - complications | Cause of Death | International Normalized Ratio | Blood Coagulation Disorders - drug therapy | Treatment Failure | Blood Coagulation Disorders - mortality | Female | Aged | Infusions, Intravenous | Thrombomodulin - therapeutic use | Control | Patient outcomes | Analysis | Clinical trials | Sepsis | Anticoagulants (Medicine) | Research | Drug delivery systems | Intensive care | Intravenous administration | Mortality | Blood cells | Erythrocytes | Hemorrhage | Bleeding | Intensive care units | Infusion | Randomization | Hospitals | Red blood cells | Etiology | Thrombomodulin | Health risk assessment | Platelets | Recombinant | Caring for the Critically Ill Patient | Online First | Original Investigation
COAGULATION | PROTEIN | MEDICINE, GENERAL & INTERNAL | Recombinant Proteins - therapeutic use | Injections, Intravenous | Blood Coagulation Disorders - etiology | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Sepsis - complications | Cause of Death | International Normalized Ratio | Blood Coagulation Disorders - drug therapy | Treatment Failure | Blood Coagulation Disorders - mortality | Female | Aged | Infusions, Intravenous | Thrombomodulin - therapeutic use | Control | Patient outcomes | Analysis | Clinical trials | Sepsis | Anticoagulants (Medicine) | Research | Drug delivery systems | Intensive care | Intravenous administration | Mortality | Blood cells | Erythrocytes | Hemorrhage | Bleeding | Intensive care units | Infusion | Randomization | Hospitals | Red blood cells | Etiology | Thrombomodulin | Health risk assessment | Platelets | Recombinant | Caring for the Critically Ill Patient | Online First | Original Investigation
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 185 - 192
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where...
Prognosis | Young adults | Chronic myeloid leukemia | Tyrosine kinase inhibitors | BCR-ABL | CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | DIAGNOSIS | MANAGEMENT | BONE-MARROW | CHILDHOOD CML | IMATINIB TREATMENT | prognosis | EUROPEAN-LEUKEMIANET | tyrosine kinase inhibitors | ONCOLOGY | RECOMMENDATIONS | young adults | CLINICAL-TRIALS | chronic myeloid leukemia | Prospective Studies | Age Factors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Young Adult | Protein Kinase Inhibitors - therapeutic use | Splenomegaly - epidemiology | Aged, 80 and over | Adult | Female | Aged | Spleen - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Prognosis | Young adults | Chronic myeloid leukemia | Tyrosine kinase inhibitors | BCR-ABL | CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | DIAGNOSIS | MANAGEMENT | BONE-MARROW | CHILDHOOD CML | IMATINIB TREATMENT | prognosis | EUROPEAN-LEUKEMIANET | tyrosine kinase inhibitors | ONCOLOGY | RECOMMENDATIONS | young adults | CLINICAL-TRIALS | chronic myeloid leukemia | Prospective Studies | Age Factors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Young Adult | Protein Kinase Inhibitors - therapeutic use | Splenomegaly - epidemiology | Aged, 80 and over | Adult | Female | Aged | Spleen - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Nature Climate Change, ISSN 1758-678X, 10/2018, Volume 8, Issue 10, pp. 907 - 913
The carbon sink potential of peatlands depends on the balance of carbon uptake by plants and microbial decomposition. The rates of both these processes will...
ENVIRONMENTAL SCIENCES | NORTHERN PEATLANDS | DECOMPOSITION | DYNAMICS | ACCUMULATION | ENVIRONMENTAL STUDIES | HOLOCENE CARBON | METEOROLOGY & ATMOSPHERIC SCIENCES | CLIMATE | CYCLE | Carbon sinks | Microorganisms | Climate | Hemispheres | Photosynthetically active radiation | Peatlands | Switches | Radiation | Growing season | Carbon | Accumulation | Uptake | Environmental Sciences | Global Changes | Samhällsvetenskap | Social och ekonomisk geografi | Naturvetenskap | Social Sciences | Social and Economic Geography | Natural Sciences | Earth and Related Environmental Sciences | Geovetenskap och miljövetenskap
ENVIRONMENTAL SCIENCES | NORTHERN PEATLANDS | DECOMPOSITION | DYNAMICS | ACCUMULATION | ENVIRONMENTAL STUDIES | HOLOCENE CARBON | METEOROLOGY & ATMOSPHERIC SCIENCES | CLIMATE | CYCLE | Carbon sinks | Microorganisms | Climate | Hemispheres | Photosynthetically active radiation | Peatlands | Switches | Radiation | Growing season | Carbon | Accumulation | Uptake | Environmental Sciences | Global Changes | Samhällsvetenskap | Social och ekonomisk geografi | Naturvetenskap | Social Sciences | Social and Economic Geography | Natural Sciences | Earth and Related Environmental Sciences | Geovetenskap och miljövetenskap
Journal Article
Biomacromolecules, ISSN 1525-7797, 03/2018, Volume 19, Issue 3, pp. 712 - 720
Dendrimers are nanosized, nonlinear, hyperbranched polymers whose overall 3D shape is key for their biological activity. Poly(PhosphorHydrazone) (PPH)...
CELLS | ACTIVATION | DESIGN | POLYMER SCIENCE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | PHOSPHORUS-CONTAINING DENDRIMERS | MOLECULAR-DYNAMICS SIMULATIONS | HUMAN MONOCYTES | Chemical Sciences | Coordination chemistry
CELLS | ACTIVATION | DESIGN | POLYMER SCIENCE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | PHOSPHORUS-CONTAINING DENDRIMERS | MOLECULAR-DYNAMICS SIMULATIONS | HUMAN MONOCYTES | Chemical Sciences | Coordination chemistry
Journal Article
Annals of Oncology, ISSN 0923-7534, 2012, Volume 23, Issue 2, pp. 501 - 508
Background: Angiosarcoma is a highly aggressive soft tissue sarcoma. Responses to anthracyclines plus/minus ifosfamide, and taxanes alone or in combination...
Chemotherapy | Gemcitabine | Sarcoma | Angiosarcoma | sarcoma | SOFT-TISSUE SARCOMAS | BONE SARCOMA | CUTANEOUS ANGIOSARCOMA | COMBINATION | chemotherapy | PACLITAXEL | BREAST-CANCER | PHASE-II TRIAL | PLUS DOCETAXEL | ONCOLOGY | LEIOMYOSARCOMA | angiosarcoma | gemcitabine | Deoxycytidine - therapeutic use | Hemangiosarcoma - drug therapy | Humans | Middle Aged | Survival Analysis | Aged, 80 and over | Adult | Aged | Retrospective Studies | Deoxycytidine - analogs & derivatives
Chemotherapy | Gemcitabine | Sarcoma | Angiosarcoma | sarcoma | SOFT-TISSUE SARCOMAS | BONE SARCOMA | CUTANEOUS ANGIOSARCOMA | COMBINATION | chemotherapy | PACLITAXEL | BREAST-CANCER | PHASE-II TRIAL | PLUS DOCETAXEL | ONCOLOGY | LEIOMYOSARCOMA | angiosarcoma | gemcitabine | Deoxycytidine - therapeutic use | Hemangiosarcoma - drug therapy | Humans | Middle Aged | Survival Analysis | Aged, 80 and over | Adult | Aged | Retrospective Studies | Deoxycytidine - analogs & derivatives
Journal Article
Haematologica, ISSN 0390-6078, 09/2016, Volume 101, Issue 10, pp. 1200 - 1207
The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored...
CHRONIC MYELOGENOUS LEUKEMIA | CLINICAL-PRACTICE GUIDELINES | RECOMMENDATIONS | IMATINIB | TYROSINE KINASE INHIBITOR | FOLLOW-UP | MOLECULAR RESPONSE | ARTERIAL OCCLUSIVE DISEASE | HEMATOLOGY | CML PATIENTS | FRONTLINE NILOTINIB | Thrombosis - chemically induced | Pyrimidines - administration & dosage | Cholesterol - blood | Humans | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Male | Treatment Outcome | Blood Glucose - drug effects | Young Adult | Protein Kinase Inhibitors - therapeutic use | Adolescent | Pyrimidines - adverse effects | Triglycerides - blood | Aged, 80 and over | Adult | Female | Remission Induction - methods | Aged
CHRONIC MYELOGENOUS LEUKEMIA | CLINICAL-PRACTICE GUIDELINES | RECOMMENDATIONS | IMATINIB | TYROSINE KINASE INHIBITOR | FOLLOW-UP | MOLECULAR RESPONSE | ARTERIAL OCCLUSIVE DISEASE | HEMATOLOGY | CML PATIENTS | FRONTLINE NILOTINIB | Thrombosis - chemically induced | Pyrimidines - administration & dosage | Cholesterol - blood | Humans | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Male | Treatment Outcome | Blood Glucose - drug effects | Young Adult | Protein Kinase Inhibitors - therapeutic use | Adolescent | Pyrimidines - adverse effects | Triglycerides - blood | Aged, 80 and over | Adult | Female | Remission Induction - methods | Aged
Journal Article